Skip to main content
Figure 2 | BMC Musculoskeletal Disorders

Figure 2

From: Rapid cell culture and pre-clinical screening of a transforming growth factor-β (TGF-β) inhibitor for orthopaedics

Figure 2

Radiographic analysis of the marrow ablation model. This model utilizes femoral reaming to induce new bone formation with femora harvested at day 10. Representative X-rays and histological sections (A) of DMSO vehicle, 1 mg/kg/day SB431542, and 25 μg/kg/day PTH1-34 treated groups are shown. Radiographs illustrate an overall increase an intramedullary bone with reaming throughout the operated limb, particularly with PTH1-34 treatment. This is also seen below the growth plate (oriented to the left) in histological sections with bone stained with Picrosirius red. To test and quantify the effects of a range of inhibitor doses in this model, DMSO vehicle, 0.1-10 mg/kg/day SB431542, and 25 μg/kg/day PTH1-34 treated groups were analyzed by pQCT (B). The marrow ablation-induced bone was analyzed by calculating the average BMC of reamed limbs relative to unreamed limbs. Only PTH1-34 treatment created a significant increase in reaming-induced bone formation (P = 0.05).

Back to article page